Biotech layoffs are slowing in 2026 compared to the previous year. BioNTech announced a major restructuring, eliminating 1,860 jobs. Vistagen reduced its workforce by 20% after a dr-g trial failure. Replimune cut 224 positions following an FDA dr-g rejection. Takeda and Merck also implemented significant job reductions due to various pressures.
https://www.pharmavoice.com/news/biotech-layoffs-pharma-dr-g-jobs/819649/